LT3130601T - Į vietą nukreipta fviii modifikacija - Google Patents
Į vietą nukreipta fviii modifikacijaInfo
- Publication number
- LT3130601T LT3130601T LTEP16186901.1T LT16186901T LT3130601T LT 3130601 T LT3130601 T LT 3130601T LT 16186901 T LT16186901 T LT 16186901T LT 3130601 T LT3130601 T LT 3130601T
- Authority
- LT
- Lithuania
- Prior art keywords
- fviii
- site
- directed modification
- modification
- directed
- Prior art date
Links
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62727704P | 2004-11-12 | 2004-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3130601T true LT3130601T (lt) | 2020-09-10 |
Family
ID=36337298
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP11153300.6T LT2363414T (lt) | 2004-11-12 | 2005-11-14 | Fviii modifikacija, nukreipta į tam tikrą vietą |
LTEP05849392.5T LT1824988T (lt) | 2004-11-12 | 2005-11-14 | Nukreipta į užduotą saitą fviii modifikacija |
LTEP11153297.4T LT2371856T (lt) | 2004-11-12 | 2005-11-14 | Fviii modifikacija, nukreipta į tam tikrą vietą |
LTEP16186901.1T LT3130601T (lt) | 2004-11-12 | 2005-11-14 | Į vietą nukreipta fviii modifikacija |
LTPA2019509C LTC1824988I2 (lt) | 2004-11-12 | 2019-05-09 | Nukreipta į užduotą saitą FVII modifikacija |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP11153300.6T LT2363414T (lt) | 2004-11-12 | 2005-11-14 | Fviii modifikacija, nukreipta į tam tikrą vietą |
LTEP05849392.5T LT1824988T (lt) | 2004-11-12 | 2005-11-14 | Nukreipta į užduotą saitą fviii modifikacija |
LTEP11153297.4T LT2371856T (lt) | 2004-11-12 | 2005-11-14 | Fviii modifikacija, nukreipta į tam tikrą vietą |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTPA2019509C LTC1824988I2 (lt) | 2004-11-12 | 2019-05-09 | Nukreipta į užduotą saitą FVII modifikacija |
Country Status (32)
Country | Link |
---|---|
US (4) | US7632921B2 (lt) |
EP (9) | EP3153181A1 (lt) |
JP (5) | JP2008524117A (lt) |
KR (7) | KR20120136413A (lt) |
CN (6) | CN105753968A (lt) |
AU (1) | AU2005304622B2 (lt) |
BR (2) | BRPI0517795B8 (lt) |
CA (1) | CA2586379C (lt) |
CY (3) | CY1119292T1 (lt) |
DK (3) | DK2371856T3 (lt) |
ES (4) | ES2821832T3 (lt) |
FR (1) | FR19C1031I2 (lt) |
HK (3) | HK1117875A1 (lt) |
HN (1) | HN2007015683A (lt) |
HR (2) | HRP20180481B1 (lt) |
HU (5) | HUE060016T2 (lt) |
IL (3) | IL182903A (lt) |
LT (5) | LT2363414T (lt) |
LU (1) | LUC00118I2 (lt) |
MA (1) | MA29663B1 (lt) |
MX (2) | MX2007005466A (lt) |
NL (1) | NL300989I2 (lt) |
NO (3) | NO20210454A1 (lt) |
NZ (1) | NZ555032A (lt) |
PH (2) | PH12014500352B1 (lt) |
PL (3) | PL2363414T3 (lt) |
PT (4) | PT3130601T (lt) |
RU (1) | RU2423380C2 (lt) |
SI (4) | SI3130601T1 (lt) |
UA (1) | UA95225C2 (lt) |
WO (1) | WO2006053299A2 (lt) |
ZA (1) | ZA200703696B (lt) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2055189A1 (en) | 2003-04-09 | 2009-05-06 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US7579444B2 (en) | 2004-06-30 | 2009-08-25 | Nektar Therapeutics Al, Corporation | Polymer-factor IX moiety conjugates |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
DK2586456T3 (en) | 2004-10-29 | 2016-03-21 | Ratiopharm Gmbh | Conversion and glycopegylation of fibroblast growth factor (FGF) |
RU2423380C2 (ru) | 2004-11-12 | 2011-07-10 | БАЙЕР ХЕЛСКЕА ЛЛСи | Сайт-направленная модификация fviii |
EP1858543B1 (en) | 2005-01-10 | 2013-11-27 | BioGeneriX AG | Glycopegylated granulocyte colony stimulating factor |
WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US8633300B2 (en) | 2005-06-17 | 2014-01-21 | Novo Nordisk Healthcare Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
RU2008145084A (ru) * | 2006-05-24 | 2010-06-27 | Ново Нордиск Хелс Кеа Аг (Ch) | Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo |
EP2049144B8 (en) | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylation of peptides via o-linked glycosylation sequences |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
JP5876208B2 (ja) | 2006-12-15 | 2016-03-02 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 延長されたinvivo半減期を有する第VIIa因子−(ポリ)シアル酸結合体 |
PL2144923T3 (pl) | 2007-04-03 | 2013-12-31 | Biogenerix Ag | Sposoby leczenia z użyciem glikopegilowanego G-CSF |
US9493499B2 (en) | 2007-06-12 | 2016-11-15 | Novo Nordisk A/S | Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography |
EP2222329A1 (en) * | 2007-11-09 | 2010-09-01 | Baxter International Inc. | Modified recombinant factor viii and von willebrand factor and methods of use |
RU2573587C2 (ru) * | 2008-02-27 | 2016-01-20 | Ново Нордиск А/С | Конъюгированные молекулы фактора viii |
KR101841870B1 (ko) | 2008-05-16 | 2018-03-23 | 바이엘 헬스케어 엘엘씨 | 표적화 응고 인자 및 그의 사용 방법 |
AU2009256093A1 (en) * | 2008-06-04 | 2009-12-10 | Bayer Healthcare Llc | FVIII muteins for treatment of von Willebrand disease |
WO2009156137A1 (en) | 2008-06-24 | 2009-12-30 | Csl Behring Gmbh | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
WO2010019263A2 (en) * | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
BRPI0920259A8 (pt) * | 2008-10-17 | 2017-09-19 | Baxter Healthcare Sa | Molécula de fator sanguíneo modificado, composição farmacêutica, e, métodos para preparar uma molécula de fator sanguíneo modificado e para tratar um indivíduo sofrendo de um distúrbio de coagulação sanguínea |
CN102202684A (zh) * | 2008-11-03 | 2011-09-28 | 拜耳医药保健有限公司 | 用于治疗血友病的方法 |
WO2010060081A1 (en) * | 2008-11-24 | 2010-05-27 | Bayer Healthcare Llc | Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay |
CA2748662A1 (en) * | 2009-01-19 | 2010-07-22 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase-cleavable bioprotective moiety |
CN116925238A (zh) | 2009-02-03 | 2023-10-24 | 阿穆尼克斯制药公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
WO2010102886A1 (en) * | 2009-02-19 | 2010-09-16 | Novo Nordisk A/S | Modification of factor viii |
HUE030373T2 (en) * | 2009-03-20 | 2017-05-29 | Hanmi Science Co Ltd | A method for producing a site-specific conjugate of a physiologically active polypeptide |
WO2010111414A1 (en) * | 2009-03-24 | 2010-09-30 | Bayer Healthcare Llc | Factor viii variants and methods of use |
HUE028056T2 (en) | 2009-07-27 | 2016-11-28 | Baxalta GmbH | Blood coagulation protein conjugates |
JP5909755B2 (ja) | 2009-07-27 | 2016-04-27 | リポクセン テクノロジーズ リミテッド | 非血液凝固タンパク質の糖ポリシアル酸化 |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
JP5908401B2 (ja) | 2009-07-27 | 2016-04-26 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 血液凝固タンパク質複合体 |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
CA2772051C (en) | 2009-08-24 | 2020-08-18 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
US9050318B2 (en) | 2009-12-06 | 2015-06-09 | Biogen Idec Hemophilia Inc. | Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof |
WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
CN102770449B (zh) | 2010-02-16 | 2016-02-24 | 诺沃—诺迪斯克有限公司 | 具有降低的vwf结合的因子viii分子 |
PL2536399T3 (pl) * | 2010-02-21 | 2020-06-29 | Bayer Healthcare Llc | Sposób aktywacji i sprzęgania biocząsteczek |
KR20180130008A (ko) | 2010-04-15 | 2018-12-05 | 올리가시스 | 고분자량 쌍성이온-함유 중합체 |
GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
EP3508573A1 (en) * | 2010-07-09 | 2019-07-10 | Bioverativ Therapeutics Inc. | Systems for factor viii processing and methods thereof |
AU2011323236B2 (en) | 2010-11-05 | 2017-03-30 | Takeda Pharmaceutical Company Limited | A new variant of antihemophilic factor VIII having increased specific activity |
US20130345403A1 (en) * | 2010-12-16 | 2013-12-26 | Novo Nordisk A/S | Aqueous factor viii solution |
EP2654794B8 (en) | 2010-12-22 | 2020-04-22 | Baxalta GmbH | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
CA2836478A1 (en) * | 2011-05-27 | 2012-12-06 | Baxter International Inc. | Therapeutic protein conjugated to water-soluble polymers via reduced cysteine sulfhydryl group |
PT2717898T (pt) | 2011-06-10 | 2019-05-20 | Bioverativ Therapeutics Inc | Compostos pró-coagulantes e processos para a sua utilização |
KR20140054009A (ko) | 2011-07-01 | 2014-05-08 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 릴랙신 융합 폴리펩타이드 및 그의 용도 |
TWI764092B (zh) | 2011-07-08 | 2022-05-11 | 美商百歐維拉提夫治療公司 | 因子viii嵌合及雜交多肽,及其使用方法 |
TWI596110B (zh) | 2011-09-23 | 2017-08-21 | 諾佛 儂迪克股份有限公司 | 新穎升糖素類似物 |
KR20130049671A (ko) * | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
ES2935489T3 (es) | 2012-02-15 | 2023-03-07 | Bioverativ Therapeutics Inc | Composiciones de factor VIII y métodos de preparación y uso de las mismas |
LT2822577T (lt) | 2012-02-15 | 2019-03-25 | Bioverativ Therapeutics Inc. | Rekombinantiniai faktoriaus viii baltymai |
DK2814502T3 (en) | 2012-02-15 | 2017-12-18 | Csl Behring Gmbh | Von Willebrand Factor variants with improved Factor VIII binding affinity |
EP2666782A1 (en) * | 2012-05-22 | 2013-11-27 | Imnate Sarl | Coagulation factor VIII with reduced immunogenicity. |
EP3693000B1 (en) | 2012-06-08 | 2022-03-02 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
US10023628B2 (en) | 2012-07-06 | 2018-07-17 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor VIII polypeptides and uses thereof |
WO2014063108A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
EP2914293A4 (en) | 2012-10-30 | 2016-04-20 | Biogen Ma Inc | METHOD OF USE OF FVIII POLYPEPTIDE |
TWI690325B (zh) | 2013-03-15 | 2020-04-11 | 美商百歐維拉提夫治療公司 | 因子viii多肽調配物 |
MX2015012905A (es) * | 2013-03-15 | 2016-06-16 | Bayer Healthcare Llc | Formulaciones de factor viii recombinantes. |
SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
CN105307672B (zh) | 2013-04-18 | 2021-01-05 | 诺和诺德股份有限公司 | 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂 |
DK2796145T3 (da) | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
TW201519900A (zh) * | 2013-04-28 | 2015-06-01 | Bayer Healthcare Llc | 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法 |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
EP3033098B1 (en) | 2013-08-14 | 2022-06-22 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
DK3041513T3 (da) | 2013-09-08 | 2020-10-26 | Kodiak Sciences Inc | Zwitterioniske faktor viii-polymerkonjugater |
BR112016009064A2 (pt) * | 2013-10-22 | 2017-09-19 | Inst Nat Sante Rech Med | Dispositivo de emplastro cutâneo; sistema de liberação de fármaco; kit; e método de tratamento da hemofilia em um indivíduo em necessidade do mesmo |
EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
RU2546297C1 (ru) * | 2013-11-19 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук | Средство, улучшающее реологические свойства крови |
EP4332839A2 (en) | 2013-12-06 | 2024-03-06 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
JP6778111B2 (ja) | 2014-01-20 | 2020-10-28 | オクタファルマ・アーゲー | FVIII:C/FVIII:Agの改良された比を有する第VIII因子を製造するための方法 |
KR102382402B1 (ko) | 2014-02-04 | 2022-04-01 | 바이오젠 엠에이 인코포레이티드 | 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도 |
WO2015132724A1 (en) * | 2014-03-05 | 2015-09-11 | Pfizer Inc. | Improved muteins of clotting factor viii |
US10772942B2 (en) | 2014-03-24 | 2020-09-15 | Bioverativ Therapeutics Inc. | Lyophilized factor IX formulations |
WO2015154090A1 (en) * | 2014-04-04 | 2015-10-08 | Bloodworks | Routine laboratory and point-of-care (poc) testing for hemostasis |
SG11201608390SA (en) | 2014-04-10 | 2016-11-29 | Bayer Healthcare Llc | Compounded media powder formulation and method of preparation of liquid medium for cell culture |
EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
US10253088B2 (en) | 2014-07-02 | 2019-04-09 | CSL Behring Lengnau AG | Modified von Willebrand Factor |
MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
WO2016142288A1 (en) | 2015-03-06 | 2016-09-15 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
DK3297656T3 (da) | 2015-05-22 | 2020-03-09 | CSL Behring Lengnau AG | Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili |
EP4089109A3 (en) | 2015-05-22 | 2023-03-01 | CSL Behring Lengnau AG | Methods for preparing modified von willebrand factor |
TWI741992B (zh) | 2015-08-03 | 2021-10-11 | 美商百歐維拉提夫治療公司 | 因子ix融合蛋白以及其製備及使用方法 |
US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
AU2017204955B2 (en) | 2016-01-07 | 2021-04-01 | CSL Behring Lengnau AG | Mutated truncated von Willebrand Factor |
SG10201912857XA (en) | 2016-01-07 | 2020-02-27 | CSL Behring Lengnau AG | Mutated von willebrand factor |
CN109689683A (zh) * | 2016-06-24 | 2019-04-26 | 财团法人牧岩生命科学研究所 | 重组单链fvⅲ及其化学缀合物 |
AU2017358861B2 (en) | 2016-11-11 | 2022-02-17 | CSL Behring Lengnau AG | Truncated von Willebrand Factor polypeptides for treating hemophilia |
ES2908008T3 (es) | 2016-11-11 | 2022-04-27 | CSL Behring Lengnau AG | Polipéptidos truncados del Factor de von Willebrand para su administración extravascular en el tratamiento o profilaxis de un trastorno de la coagulación sanguínea |
MX2019005693A (es) | 2016-11-16 | 2019-08-14 | Bayer Healthcare Llc | Factor viii direccionado a los globulos rojos y metodo para su uso. |
CN110520149A (zh) | 2016-12-02 | 2019-11-29 | 比奥维拉迪维治疗股份有限公司 | 诱导对凝血因子的免疫耐受性的方法 |
US20190381149A1 (en) | 2016-12-02 | 2019-12-19 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
MX2019009063A (es) | 2017-01-31 | 2019-10-21 | Bioverativ Therapeutics Inc | Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas. |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
KR20190086269A (ko) * | 2018-01-12 | 2019-07-22 | 재단법인 목암생명과학연구소 | 체내 지속형 재조합 당단백질 및 이의 제조방법 |
TW202015723A (zh) | 2018-05-18 | 2020-05-01 | 美商百歐維拉提夫治療公司 | 治療a型血友病的方法 |
AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
WO2021091881A1 (en) * | 2019-11-04 | 2021-05-14 | The Trustees Of Columbia University In The City Of New York | High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof |
CN114828870A (zh) * | 2019-12-06 | 2022-07-29 | 费城儿童医院 | 用于调节因子viii功能的组合物和方法 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59172425A (ja) * | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤 |
US7138505B1 (en) | 1984-01-12 | 2006-11-21 | Novartis Vaccines And Diagnostics, Inc. | Factor VIII:C nucleic acid molecules |
US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
US5422260A (en) | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
US5451521A (en) | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
US5171844A (en) | 1987-06-12 | 1992-12-15 | Gist-Brocades N.W. | Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
EP0690126B1 (en) | 1987-06-12 | 2001-11-28 | Baxter Aktiengesellschaft | Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
AU2473388A (en) * | 1987-11-16 | 1989-06-22 | Scripps Clinic And Research Foundation | Treatment of factor viii inhibitors |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
ATE198277T1 (de) | 1992-10-02 | 2001-01-15 | Genetics Inst | Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator |
AU6029594A (en) * | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
AU685187B2 (en) | 1993-10-29 | 1998-01-15 | Incyte Pharmaceuticals, Inc. | Chimeric proteins including protease nexin-1 variants |
IL113010A0 (en) | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
BE1008491A3 (fr) * | 1994-07-14 | 1996-05-07 | Croix Rouge De Belgique Depart | Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci. |
WO1996041813A2 (en) | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
CA2198111C (en) * | 1995-06-21 | 2000-01-11 | James Patrick Phillips | Method and antenna for providing an omnidirectional pattern |
WO1997003195A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered protease sites |
SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
AT403438B (de) | 1996-05-24 | 1998-02-25 | Immuno Ag | Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität |
US6458563B1 (en) * | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
DE69736780T2 (de) * | 1996-08-02 | 2007-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Polypeptide mit einzelnem kovalent gebundenen n-terminalen wasserlöslichen polymer |
CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
AU751898B2 (en) | 1997-07-14 | 2002-08-29 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
JP2001520198A (ja) * | 1997-10-17 | 2001-10-30 | ハーベスト・テクノロジーズ・コーポレイション | 血小板富有血漿からの成長因子富有化フィブリノーゲン濃縮物の調製 |
EP0922446A1 (en) | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
CA2329768C (en) | 1998-04-27 | 2008-06-10 | Opperbas Holding B.V. | Pharmaceutical composition comprising factor viii and neutral liposomes |
US6759216B1 (en) | 1998-11-06 | 2004-07-06 | Emory University | Glycosylated, low antigenicity low immunogenicity factor VIII |
WO2000028021A1 (de) | 1998-11-10 | 2000-05-18 | Baxter Aktiengesellschaft | Ein faktor viii-polypeptid mit faktor viii:c-aktivität |
US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
US6136599A (en) | 1998-12-10 | 2000-10-24 | Bayer Corporation | Human hybrid host cell for mammalian gene expression |
EP1144613B2 (en) | 1999-01-14 | 2020-05-06 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
AU5282200A (en) | 1999-05-24 | 2000-12-12 | American National Red Cross, The | Methods of reducing factor viii clearance and compositions therefor |
PL204285B1 (pl) * | 2000-02-11 | 2009-12-31 | Bayer Healthcare Llc | Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego |
PL206105B1 (pl) | 2000-09-19 | 2010-07-30 | Emory Universityemory University | Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej |
US7615622B2 (en) | 2001-01-12 | 2009-11-10 | University Of Maryland, Baltimore | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII |
BR0208203A (pt) * | 2001-03-22 | 2005-04-19 | Novo Nordisk Healthcare Ag | Polipeptìdeo do fator vii, derivado do fator vii, composição, composição farmacêutica, construção de polinucleotìdeo, célula hospedeira eucariótica, animal transgênico, planta transgênica, e, métodos para produzir o polipeptìdeo do fator vii e um derivado do fator vii, uso de um derivado do fator vii, métodos para o tratamento de episódios de hemorragia ou distúrbios de hemorragia em um paciente ou para a intensificação do sistema hemostático normal e para inibir a formação de trobo em um paciente |
WO2002096454A1 (en) | 2001-05-31 | 2002-12-05 | D. Collen Research Foundation Vzw | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
WO2002098454A2 (en) | 2001-05-31 | 2002-12-12 | D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
WO2002103024A2 (en) | 2001-06-14 | 2002-12-27 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
AU2002337901B2 (en) | 2001-10-05 | 2008-01-17 | Expression Therapeutics Llc | Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use |
RU2004133761A (ru) | 2002-04-18 | 2005-07-10 | Мерк Патент ГмбХ (DE) | Модифицированный фактор viii |
JP4412461B2 (ja) | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
US8003117B2 (en) | 2002-11-20 | 2011-08-23 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
AU2003300139B2 (en) | 2002-12-31 | 2008-08-28 | Nektar Therapeutics | Maleamic acid polymer derivatives and their bioconjugates |
KR101025143B1 (ko) | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | 가수분해상으로 안정한 말레이미드-종결 중합체 |
DE602004029646D1 (en) | 2003-01-06 | 2010-12-02 | Nektar Therapeutics San Carlos | Thiolselektive wasserlösliche polymerderivate |
EP1596887B1 (en) * | 2003-02-26 | 2022-03-23 | Nektar Therapeutics | Polymer-factor viii moiety conjugates |
US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
US20040180054A1 (en) | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
WO2004101600A2 (en) | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Novel poly(ethylene glycol) modified compounds and uses thereof |
EP1626741A2 (en) | 2003-05-23 | 2006-02-22 | Nektar Therapeutics Al, Corporation | Peg derivatives having an amidocarbonate linkage |
EP1502921A1 (en) | 2003-07-29 | 2005-02-02 | ZLB Behring GmbH | Recombinant mutated human factor VIII (FVIII) with improved stability |
WO2005046583A2 (en) | 2003-10-30 | 2005-05-26 | Emory University | Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes |
US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
EP1699469B1 (en) | 2003-12-03 | 2010-04-07 | University of Rochester | Recombinant factor viii having increased specific activity |
WO2006027111A1 (en) | 2004-09-06 | 2006-03-16 | Zlb Behring Gmbh | Modified coagulation factor viii with enhanced stability |
RU2423380C2 (ru) | 2004-11-12 | 2011-07-10 | БАЙЕР ХЕЛСКЕА ЛЛСи | Сайт-направленная модификация fviii |
EP1871801A2 (en) | 2005-04-01 | 2008-01-02 | Novo Nordisk Health Care AG | Blood coagulation fviii analogues |
US7645860B2 (en) * | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
AU2007245190B2 (en) * | 2006-03-31 | 2011-07-21 | Takeda Pharmaceutical Company Limited | Pegylated factor VIII |
-
2005
- 2005-11-14 RU RU2007121517/10A patent/RU2423380C2/ru active
- 2005-11-14 KR KR1020127028644A patent/KR20120136413A/ko not_active Application Discontinuation
- 2005-11-14 HU HUE11153300A patent/HUE060016T2/hu unknown
- 2005-11-14 EP EP16186902.9A patent/EP3153181A1/en not_active Withdrawn
- 2005-11-14 DK DK11153297.4T patent/DK2371856T3/da active
- 2005-11-14 US US11/273,896 patent/US7632921B2/en active Active
- 2005-11-14 BR BRPI0517795A patent/BRPI0517795B8/pt active IP Right Grant
- 2005-11-14 SI SI200532283T patent/SI3130601T1/sl unknown
- 2005-11-14 NZ NZ555032A patent/NZ555032A/en unknown
- 2005-11-14 HU HUE11153297A patent/HUE059193T2/hu unknown
- 2005-11-14 KR KR1020147018134A patent/KR101654011B1/ko active IP Right Grant
- 2005-11-14 CN CN201610201090.XA patent/CN105753968A/zh active Pending
- 2005-11-14 CN CN2005800464698A patent/CN101124331B/zh active Active
- 2005-11-14 HR HRP20180481AA patent/HRP20180481B1/hr active IP Right Grant
- 2005-11-14 LT LTEP11153300.6T patent/LT2363414T/lt unknown
- 2005-11-14 JP JP2007541405A patent/JP2008524117A/ja active Pending
- 2005-11-14 NO NO20210454A patent/NO20210454A1/no unknown
- 2005-11-14 DK DK11153300.6T patent/DK2363414T3/da active
- 2005-11-14 KR KR1020187027821A patent/KR20180110192A/ko not_active Application Discontinuation
- 2005-11-14 UA UAA200706559A patent/UA95225C2/ru unknown
- 2005-11-14 BR BR122016022033A patent/BR122016022033B8/pt active IP Right Grant
- 2005-11-14 EP EP17201672.7A patent/EP3323829B1/en active Active
- 2005-11-14 LT LTEP05849392.5T patent/LT1824988T/lt unknown
- 2005-11-14 CN CN201510612184.1A patent/CN105148287B/zh active Active
- 2005-11-14 AU AU2005304622A patent/AU2005304622B2/en active Active
- 2005-11-14 EP EP17170687.2A patent/EP3243834A1/en not_active Withdrawn
- 2005-11-14 CA CA2586379A patent/CA2586379C/en active Active
- 2005-11-14 ES ES16186901T patent/ES2821832T3/es active Active
- 2005-11-14 ES ES11153300T patent/ES2930159T3/es active Active
- 2005-11-14 PT PT161869011T patent/PT3130601T/pt unknown
- 2005-11-14 EP EP05849392.5A patent/EP1824988B1/en active Active
- 2005-11-14 ES ES11153297T patent/ES2930143T3/es active Active
- 2005-11-14 LT LTEP11153297.4T patent/LT2371856T/lt unknown
- 2005-11-14 NO NO20200044A patent/NO345800B1/no unknown
- 2005-11-14 KR KR1020137007423A patent/KR101468345B1/ko active Protection Beyond IP Right Term
- 2005-11-14 CN CN201610838893.6A patent/CN107082806A/zh active Pending
- 2005-11-14 PT PT111532974T patent/PT2371856T/pt unknown
- 2005-11-14 HU HUE16186901A patent/HUE050542T2/hu unknown
- 2005-11-14 PL PL11153300.6T patent/PL2363414T3/pl unknown
- 2005-11-14 KR KR1020167023706A patent/KR101904630B1/ko active IP Right Grant
- 2005-11-14 EP EP11153300.6A patent/EP2363414B1/en active Active
- 2005-11-14 PL PL11153297.4T patent/PL2371856T3/pl unknown
- 2005-11-14 CN CN201310125428.4A patent/CN103214569B/zh active Active
- 2005-11-14 ES ES05849392.5T patent/ES2633916T3/es active Active
- 2005-11-14 EP EP16186901.1A patent/EP3130601B1/en active Active
- 2005-11-14 EP EP14165736.1A patent/EP2772500B1/en not_active Revoked
- 2005-11-14 HU HUE05849392A patent/HUE033776T2/en unknown
- 2005-11-14 LT LTEP16186901.1T patent/LT3130601T/lt unknown
- 2005-11-14 SI SI200532308T patent/SI2363414T1/sl unknown
- 2005-11-14 WO PCT/US2005/041205 patent/WO2006053299A2/en active Search and Examination
- 2005-11-14 SI SI200532309T patent/SI2371856T1/sl unknown
- 2005-11-14 CN CN201210455152.1A patent/CN103102406B/zh active Active
- 2005-11-14 MX MX2007005466A patent/MX2007005466A/es active IP Right Grant
- 2005-11-14 MX MX2014005051A patent/MX350293B/es unknown
- 2005-11-14 PL PL05849392T patent/PL1824988T3/pl unknown
- 2005-11-14 DK DK05849392.5T patent/DK1824988T3/en active
- 2005-11-14 EP EP17166910.4A patent/EP3243833B1/en active Active
- 2005-11-14 PT PT111533006T patent/PT2363414T/pt unknown
- 2005-11-14 KR KR1020147002721A patent/KR101483917B1/ko active IP Right Grant
- 2005-11-14 EP EP11153297.4A patent/EP2371856B1/en active Active
- 2005-11-14 KR KR1020077013131A patent/KR101243564B1/ko active Protection Beyond IP Right Term
- 2005-11-14 PT PT58493925T patent/PT1824988T/pt unknown
- 2005-11-14 SI SI200532158T patent/SI1824988T1/sl unknown
-
2007
- 2007-05-01 IL IL182903A patent/IL182903A/en active IP Right Grant
- 2007-05-08 ZA ZA200703696A patent/ZA200703696B/xx unknown
- 2007-05-11 HN HN2007015683A patent/HN2007015683A/es unknown
- 2007-06-06 MA MA29972A patent/MA29663B1/fr unknown
- 2007-06-08 HR HRP20070268AA patent/HRP20070268B1/hr active IP Right Grant
- 2007-06-12 NO NO20072997A patent/NO344606B1/no unknown
-
2008
- 2008-07-15 HK HK08107795.4A patent/HK1117875A1/xx unknown
-
2009
- 2009-08-13 US US12/540,703 patent/US9364520B2/en active Active
-
2012
- 2012-10-19 JP JP2012231926A patent/JP6109523B2/ja active Active
-
2013
- 2013-01-24 US US13/748,983 patent/US9096656B2/en active Active
- 2013-08-13 HK HK13109463.4A patent/HK1182121A1/xx unknown
-
2014
- 2014-02-12 PH PH12014500352A patent/PH12014500352B1/en unknown
- 2014-05-11 IL IL232540A patent/IL232540A/en active IP Right Grant
- 2014-09-02 IL IL23443314A patent/IL234433B/en active IP Right Grant
-
2015
- 2015-02-09 JP JP2015022993A patent/JP6018238B2/ja active Active
- 2015-07-20 US US14/803,677 patent/US20160051633A1/en not_active Abandoned
-
2016
- 2016-06-13 HK HK16106727.9A patent/HK1218718A1/zh unknown
- 2016-12-02 JP JP2016234756A patent/JP6487895B2/ja active Active
- 2016-12-02 JP JP2016234757A patent/JP6559642B2/ja active Active
-
2017
- 2017-07-14 CY CY20171100753T patent/CY1119292T1/el unknown
-
2019
- 2019-05-07 FR FR19C1031C patent/FR19C1031I2/fr active Active
- 2019-05-07 HU HUS1900026C patent/HUS1900026I1/hu unknown
- 2019-05-08 LU LU00118C patent/LUC00118I2/fr unknown
- 2019-05-09 LT LTPA2019509C patent/LTC1824988I2/lt unknown
- 2019-05-10 NL NL300989C patent/NL300989I2/nl unknown
- 2019-05-10 CY CY2019024C patent/CY2019024I1/el unknown
- 2019-07-09 PH PH12019501613A patent/PH12019501613A1/en unknown
-
2020
- 2020-10-05 CY CY20201100928T patent/CY1123384T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1900026I1 (hu) | FVIII helyspecifikus módosítása | |
EP1785131A4 (en) | EXTERNAL PREPARATION OF TYPE S / O | |
GB0524619D0 (en) | Improved osteotome | |
EP1773871A4 (en) | COMPOUNDS ASSOCIATED WITH TISSUE DIFFERENTIATION FACTOR AND THEIR ANALOGUES | |
ZA200606315B (en) | Novel amido-substituted hydroxy-6-phenylphenanthridines | |
EP1731147A4 (en) | EXTERNAL PREPARATION | |
PL1720633T3 (pl) | Płuczka wieżowa gazu | |
GB0428026D0 (en) | Infant aid | |
AU300055S (en) | Scrubber | |
GB2416051B (en) | Selection of component | |
ZA200508325B (en) | Manufacture of kerbstones | |
GB0421155D0 (en) | Piece of mind plan | |
GB0415217D0 (en) | Compounds and uses thereof | |
GB0412872D0 (en) | Novel structures | |
PL369353A1 (pl) | Zestaw elementów budowlanych | |
AU157294S (en) | External cornice corner member | |
TWM275831U (en) | Improved structure of cinerary urn |